Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise
NCT ID: NCT01113710
Last Updated: 2012-09-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
687 participants
OBSERVATIONAL
2010-05-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Last Observation Carried Forward (LOCF) method was utilized for all outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neupro®
Routine treatment in accordance with the local marketing authorization for Neupro® in RLS
Neupro®
Neupro® is the exposure/intervention of interest in this non-interventional study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neupro®
Neupro® is the exposure/intervention of interest in this non-interventional study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must have a diagnosis of moderate to severe idiopathic RLS
* The patient is considered reliable and capable of adhering to the visit schedule or medication administration according to the judgment of the investigator
* The decision to prescribe the drug has been made by the physician independently of his/her decision to include the patient in the study
* Subject is informed and given ample time and opportunity to think about his/her participation in the study and has given written informed data consent
Exclusion Criteria
* Magnetic resonance imaging or cardioversion (see SmPC)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abensburg, , Germany
Altenholz, , Germany
Alzenau in Unterfranken, , Germany
Anklam, , Germany
Aschaffenburg, , Germany
Bad Neustadt an der Saale, , Germany
Berlin, , Germany
Bielefeld, , Germany
Bischofswerda, , Germany
Bochum, , Germany
Bonn, , Germany
Böblingen, , Germany
Bremen, , Germany
Cologne, , Germany
Cottbus, , Germany
Delbrück, , Germany
Dippoldiswalde, , Germany
Dortmund-Kirchhörde, , Germany
Dresden, , Germany
Düren, , Germany
Ellwangen, , Germany
Erbach im Odenwald, , Germany
Freiburg im Breisgau, , Germany
Fulda, , Germany
Gelsenkirchen, , Germany
Gera, , Germany
Gladenbach, , Germany
Göttingen, , Germany
Greifswald, , Germany
Gütersloh, , Germany
Halle, , Germany
Heidenheim, , Germany
Ilmenau, , Germany
Jülich, , Germany
Karlsruhe, , Germany
Karlstadt am Main, , Germany
Kassel, , Germany
Kaufbeuren, , Germany
Kleve, , Germany
Königsbrück, , Germany
Leipzig, , Germany
Lemgo, , Germany
Leun-Biskirchen, , Germany
Lippstadt, , Germany
Lohr a. Main, , Germany
Ludwigsfelde, , Germany
Malchin, , Germany
Mannheim, , Germany
Marburg, , Germany
Marburg-Cappel, , Germany
München, , Germany
Neuburg an der Donau, , Germany
Neusäß, , Germany
Oberursel, , Germany
Oelde, , Germany
Osnabrück, , Germany
Osterode am Harz, , Germany
Paderborn, , Germany
Potsdam, , Germany
Remscheid, , Germany
Rheda-Wiedenbrück, , Germany
Rostock, , Germany
Schriesheim, , Germany
Schwalmstadt-Treysa, , Germany
Schwäbisch Gmünd, , Germany
Schwedt, , Germany
Schwerin, , Germany
Senftenberg, , Germany
Soest, , Germany
Stadtroda, , Germany
Stralsund, , Germany
Stuttgart, , Germany
Teupitz, , Germany
Ulm, , Germany
Westerstede, , Germany
Wiesbaden, , Germany
Wismar, , Germany
Wolfsburg, , Germany
Zschadrass, , Germany
Zwickau, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stiasny-Kolster K, Berg D, Hofmann WE, Berkels R, Grieger F, Lauterbach T, Schollmayer E, Bachmann CG. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany. Sleep Med. 2013 Jun;14(6):475-81. doi: 10.1016/j.sleep.2013.02.013. Epub 2013 May 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP0948
Identifier Type: -
Identifier Source: org_study_id